Balancing gains in progression-free survival with complexity and toxicity

More treatment doesn't automatically mean better treatment, Poh stresses, and the combinations that can improve progression-free survival come with the risks of additional toxicity and treatment complexity. The addition of tafasitamab means additional infusions, and with that, the potential for infusion-related or immune-mediated toxicities. With epcoritamab, a bispecific antibody, there is the risk of cytokine release syndrome, she notes. Poh says in discussing the treatments with patients she tries to put the benefit less in absolute terms and talk instead about how much additional disease control might be expected and what might be given to achieve that benefit. She says she also considers the goals of patients, and that is a shared decision-making process.